Stereotaxis (STXS) Company Report

Stereotaxis reported Q3 2025 total revenue of $7.5 million, consisting of $1.9 million in system revenue and $5.6 million in recurring revenue, resulting in an operating loss of ($6.6) million and a net loss of ($6.5) million.
As of September 30, 2025, the company held $10.5 million in cash and cash equivalents and had no debt.
For Q4 2025, Stereotaxis expects revenue to exceed $9 million, with system revenue of approximately $3 million and recurring revenue greater than $6 million, projecting over 20% annual revenue growth for the current year.
The company announced U.S. FDA regulatory clearance for the GenesisX robotic system and secured two new Genesis robotic system orders from European hospitals.

Nov 12, 2025, 2:00 PM

Stereotaxis Reports Third Quarter 2025 Financial Results

STXS

Earnings

Guidance Update

Product Launch

For the third quarter ended September 30, 2025, Stereotaxis reported total revenue of $7.5 million, comprising $1.9 million in system revenue and $5.6 million in recurring revenue. The company recorded an operating loss of ($6.6) million and a net loss of ($6.5) million for the quarter.
As of September 30, 2025, Stereotaxis held $10.5 million in cash and cash equivalents and had no debt.
Key product and regulatory milestones include the U.S. FDA regulatory clearance for the GenesisX robotic system, European CE Mark receipt and FDA submission for Synchrony digital cath lab technology, and initial sales of the MAGiC ablation catheter and MAGiC Sweep high-density mapping catheter.
Stereotaxis anticipates revenue in the fourth quarter of 2025 to exceed $9 million, with annual revenue growth for 2025 projected to be over 20%. The company expects quarterly revenue to surpass an average of $10 million per quarter in 2026.

Nov 11, 2025, 9:01 PM

Stereotaxis Receives U.S. FDA Clearance for GenesisX Robotic System

STXS

Product Launch

New Projects/Investments

Stereotaxis (NYSE: STXS) announced on November 10, 2025, that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its latest generation robotic system, GenesisX™.
GenesisX features a compact design with integrated magnetic shielding, operates on standard power, requires no structural anchoring, and has an 80% smaller system cabinet, enabling installation in existing cath labs without complex construction.
Chairman and CEO David Fischel highlighted this as a landmark approval that will transform the accessibility and scalability of Robotic Magnetic Navigation, aiming to pioneer broad robotic adoption across endovascular surgery.
Stereotaxis has initiated a limited launch of GenesisX in the United States and Europe, while simultaneously expanding its portfolio of compatible catheters and enhancing operational processes for a full launch.

Nov 10, 2025, 9:05 PM

Stereotaxis Gains FDA 510(k) Clearance for GenesisX Robotic System

STXS

Product Launch

New Projects/Investments

Demand Weakening

Stereotaxis has achieved FDA 510(k) clearance for its GenesisX robotic platform, designed to enhance accessibility and efficiency in endovascular surgery.
The GenesisX system features a compact, lightweight design with integrated magnetic shielding, allowing installation in standard cath labs without requiring room modifications or structural anchoring.
A limited launch of GenesisX has been initiated in the U.S. and Europe, with plans to expand the catheter portfolio and commercial processes ahead of a full market rollout.
Despite these technological advancements, Stereotaxis faces financial challenges, including declining revenue growth.

Nov 10, 2025, 8:12 PM

Stereotaxis Announces EU Approval and US Submission for Synchrony System

STXS

Product Launch

New Projects/Investments

Stereotaxis announced it obtained CE Mark in Europe and submitted a 510(k) application to the FDA in the US for its new Synchrony™ system.
The Synchrony system is designed to digitize and modernize interventional cath labs through a 55” 4K ultra-high-definition display and streamlined workflows.
It is accompanied by SynX™, a cloud-based app providing secure remote connectivity, collaboration, and monitoring for cath labs.
The system is positioned as a foundational platform for future innovations, including artificial intelligence integration and supporting remote long-distance robotic procedures.

Oct 15, 2025, 11:32 AM

Stereotaxis and CardioFocus Announce Collaboration for Robotic PFA Technology

STXS

New Projects/Investments

Product Launch

Stereotaxis and CardioFocus, Inc. have entered into a Collaboration Agreement to advance robotic Pulsed Field Ablation (PFA) technology towards commercialization for the treatment of cardiac arrhythmias.
The collaboration combines CardioFocus’ Centauri Pulsed Field Ablation (PFA) System with Stereotaxis’ MAGiC robotic cardiac ablation catheter to create the first-ever robotic PFA solution.
The companies have successfully completed extensive bench and preclinical testing, including pivotal preclinical studies that demonstrated safe, efficient, and impressive lesion delivery.
The agreement supports advancing this joint solution to a clinical trial, facilitating regulatory compatibility, and commercial availability.

Oct 13, 2025, 11:34 AM

Stereotaxis Completes First US Commercial Robotic HD Mapping Procedures

STXS

Product Launch

Stereotaxis successfully completed the world's first procedures using MAGiC Sweep™, a robotically-navigated high-density electrophysiology (EP) mapping catheter, at Deborah Heart and Lung Center.
The MAGiC Sweep catheter enables the creation of a more accurate and detailed map of complex anatomy, offering easy navigation, stable tissue contact, and clear electrogram signals.
Stereotaxis has initiated the commercial launch of MAGiC Sweep in the United States following recent FDA clearance, and it has been submitted for regulatory clearance in Europe.